Delving into the Latest Updates on SBI-0797750 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

PfGluPho

Action

inhibitors

Mechanism

PfGluPho inhibitors(PfGluPho inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Malaria

Inactive Indication-

Originator Organization

Sanford Burnham Prebys Medical Discovery Institute

Active Organization

Sanford Burnham Prebys Medical Discovery Institute

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Maloney, Patrick ; Valente, Elena ; Pinkerton, Anthony B. ; Rahlfs, Stefan ; Simula, Luigi Felice ; Ulliers, Daniela ; Preuss, Janina ; Gosalia, Palak ; Rahbari, Mahsa ; Peddibhotla, Satyamaheshwar ; Berneburg, Isabell ; Jackson, Michael R. ; Buchholz, Kathrin ; Schwarzer, Evelin ; Chung, Thomas D. Y. ; Haeussler, Kristina ; Bode, Lars ; Hershberger, Paul ; Heimsch, Kim C. ; Skorokhod, Oleksii ; Hedrick, Michael P. ; Becker, Katja

In Plasmodium , the first two and rate-limiting enzymes of the pentose phosphate pathway, glucose 6-phosphate dehydrogenase (G6PD) and the 6-phosphogluconolactonase, are bifunctionally fused to a unique enzyme named GluPho, differing structurally and mechanistically from the respective human orthologs. Consistent with the enzyme’s essentiality for malaria parasite proliferation and propagation, human G6PD deficiency has immense impact on protection against severe malaria, making Pf GluPho an attractive antimalarial drug target.

100 Deals associated with SBI-0797750

Login to view more data